查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1372749

干癣药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按治疗类型、作用机制、给药途径、地区、竞争细分

Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 Segmented By Type of Treatment, By Mechanism of Action, By Route of Administration, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球干癣药物市场估值达210.6亿美元，预计在未来一段时间内大幅成长，预计到2028年复合年增长率（CAGR）为6.57%。全球干癣药物市场代表製药业中一个充满活力且快速发展的部门，主要是由于银屑病患病率不断上升、治疗方案的进步以及对更有效的治疗干预措施的需求不断增长而推动的。本市场概述提供了对现状以及塑造全球银屑病药物市场的关键因素的见解。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 210.6亿美元
2028 年市场规模 307.9亿美元
2023-2028 年复合年增长率 6.57%
成长最快的细分市场 口服
最大的市场 北美洲

牛皮癣盛行率增加

牛皮癣盛行率的增加是指全世界被诊断出患有这种慢性自体免疫性皮肤病的人数不断增加。牛皮癣的特征是皮肤细胞快速积聚，导致脱皮、发红和发炎等症状。牛皮癣有遗传因素，有家族病史的人更有可能患上牛皮癣。随着家庭的扩大和遗传讯息的传承，牛皮癣病例的可能性增加。

环境触发因素，例如压力、吸烟和某些感染，可能会加剧牛皮癣或引发其发作。在我们的现代生活方式中，接触这些触发因素变得越来越普遍，导致盛行率不断增加。饮食习惯的改变、久坐的生活方式以及接触污染和城市环境的增加可能会影响牛皮癣的发展。这些生活方式因素会影响免疫系统和皮肤健康，可能导致牛皮癣。医学知识和诊断技术的进步使牛皮癣病例得到了更好的识别和诊断。医疗保健提供者现在更善于识别这种疾病，即使是较轻微的形式，这导致盛行率明显上升。

研究与开发的进步

製药业的研发 (R&D) 工作取得了显着进步，特别是在皮肤病学和自体免疫疾病领域。这些进步包括对银屑病分子机制的更深入了解、新药物标靶的发现以及更有针对性和更有效的疗法的开发。研发的进步对于推动市场成长至关重要，因为它们可以创造出更好的牛皮癣药物。这些创新提高了药物的疗效、减少了副作用并改善了患者的治疗效果。创新疗法的承诺鼓励了对牛皮癣药物市场的投资，吸引了製药公司和投资者。

不断变化的监管环境

负责药品审批的监管机构已经适应了不断变化的医疗保健环境。他们认识到迫切需要安全有效的牛皮癣治疗方法。因此，批准牛皮癣药物的监管程序变得更加高效和宽鬆。不断发展的监管环境对于市场成长至关重要，因为它加快了新的牛皮癣药物上市所需的时间。简化审批意味着製药公司可以更快地将其产品商业化，从而更迅速地满足患者的需求并保持市场竞争力。

提高患者意识

如今，患者可以更多地获取有关牛皮癣及其可用治疗方法的资讯。这主要归功于网路、病患权益团体和医疗保健教育措施。患者越来越主动地寻求治疗方案并倡导他们的医疗保健需求。患者意识的提高是市场成长的重要推动力，因为知情的患者更有可能为牛皮癣寻求医疗协助。他们积极与医疗保健提供者合作，从而实现更早的诊断和治疗。这一趋势不仅使患者受益，也刺激了对牛皮癣药物的需求。

主要市场挑战

对牛皮癣原因和触发因素的了解有限

牛皮癣是一种多因素自体免疫疾病，其确切原因仍不清楚。其病理生理学的复杂性使得开发标靶疗法具有挑战性。牛皮癣发作可能由多种因素引发或加剧，包括压力、感染和生活方式的选择。单独理解和解决这些触发因素是一项复杂的任务。

遗传倾向在银屑病中发挥作用，但涉及的遗传因素是多种多样的。根据特定基因谱量身订做治疗方法是限制个人化治疗发展的挑战。

研发成本高

开发新的牛皮癣药物需要进行广泛的临床试验以确保安全性和有效性。这些试验成本高昂且耗时，通常需要数年时间才能完成。

满足药品（包括牛皮癣治疗）的严格监管要求需要大量的财务投资。这可能会阻止规模较小的製药公司进入市场。製药业的竞争本质意味着公司需要在研发方面进行大量投资才能保持领先地位。这种高水准的竞争可能对小公司构成障碍。

获得治疗和医疗保健的差距

一些针对牛皮癣的新型生物疗法可能非常昂贵，限制了没有全面保险范围的个人的使用。负担能力问题可能会减缓市场的成长潜力。

银屑病治疗的获得情况可能因地区而异。在服务不足的地区或医疗基础设施有限的国家，患者可能难以获得适当的护理，从而阻碍市场扩张。患者和医疗保健提供者缺乏对银屑病的认识和教育可能会导致治疗延迟或次优。努力提高认识和理解对于市场成长至关重要。

主要市场趋势

生物疗法占主导地位的治疗方法：

全球银屑病市场的一个显着趋势是生物疗法的使用不断增加。生物製剂是一种源自活生物体的药物，针对牛皮癣涉及的特定免疫系统成分。与类固醇等传统治疗方法相比，它们在控制牛皮癣症状方面表现出显着的功效，而且副作用较少。因此，市场正在见证向生物疗法的转变，为患者提供更有效、更有针对性的治疗选择。

个人化医疗和精准治疗：

个人化医疗在牛皮癣的治疗中越来越受到关注。遗传学和生物标记研究的进步使医疗保健提供者能够根据个别患者的特定遗传和分子特征量身定制治疗方案。这种趋势允许更精确和有效的治疗，最大限度地减少试错方法并改善患者的治疗结果。

远距医疗和数位健康解决方案：

远距医疗和数位健康解决方案在银屑病市场的采用加速，尤其是在 COVID-19 大流行之后。患者现在可以更好地与皮肤科医生和医疗保健提供者进行远端咨询。此外，数位工具和行动应用程式可以帮助患者追踪他们的牛皮癣症状和治疗进度。这一趋势增强了患者对银屑病的参与、监测和整体管理，提高了护理品质和患者体验。

这些趋势反映了全球银屑病市场正在朝着更有效、以患者为中心、技术先进的银屑病管理方法不断发展。它们标誌着银屑病患者朝着更好的结果和改善的生活品质的积极转变。

细分市场洞察

治疗类型见解

根据治疗类型，生物药物细分市场将于 2022 年成为全球银屑病药物市场的主导者。生物药物在全球银屑病药物市场中的主导地位可归因于与其治疗类型相关的几个关键因素。生物药物旨在针对在牛皮癣发展中发挥作用的免疫系统的特定组成部分。与皮质类固醇或外用乳膏等非生物治疗相比，这种有针对性的方法可以带来更高的治疗效果和更有利的副作用。

生物药物通常以较低的给药频率提供更持久的效果。有些生物製剂需要每隔几週或几个月注射或输注，与每天或更频繁地使用其他药物相比，减轻了患者的治疗负担。生物製剂通常引起全身副作用的风险较低，因为它们专门作用于与牛皮癣有关的免疫系统成分。这与口服皮质类固醇等全身性治疗形成鲜明对比，后者可能产生更广泛且可能更严重的副作用。

生物药物在减轻牛皮癣的身体和心理负担方面显示出显着疗效。患者的生活品质通常会显着改善，包括搔痒、疼痛和发炎减少，以及皮肤外观改善。这种对患者健康的正面影响推动了对生物製剂的需求。随着患者对治疗方案及其结果的了解越来越多，许多人由于生物製剂的有效性和安全性而表达了对生物製剂的偏好。这种患者偏好促成了生物药物在市场上的主导地位。由于广泛的临床研究支持生物製剂的有效性和安全性，医疗保健提供者对处方生物製剂治疗牛皮癣有了信心。医生的这种信心进一步促进了生物製剂的使用。製药公司在研发方面投入巨资，以创造和改进牛皮癣的生物疗法。这种持续的创新导致了具有增强特性的新型生物製剂的开发，进一步巩固了其在市场上的主导地位。预计这些因素将推动该领域的成长。

行动洞察机制

根据作用机制，白细胞介素抑制剂将在 2022 年成为全球银屑病药物市场的主导者。白细胞介素抑制剂专门针对参与银屑病发展的免疫途径。牛皮癣的特征是免疫反应过度活跃，其中白细胞介素发挥至关重要的作用。透过抑制这些特定的白血球介素，例如 IL-17 和 IL-23，这些药物可以有效地从根本上破坏疾病进程。白细胞介素抑制剂在临床试验中显示出显着的功效，通常可以快速改善牛皮癣症状。开始治疗后不久，患者常常会发现发炎、搔痒和皮肤损伤明显减轻。

许多白细胞介素抑制剂的作用持续时间较长，因此可以减少给药频率。此类药物中的一些药物需要每隔几週或几个月注射或输註一次，为患者提供便利性并提高依从性。白细胞介素抑制剂已显示出能够维持许多患者的病情缓解，并降低牛皮癣发作的风险。此功能对于寻求长期疾病控制的个人特别有价值。与口服皮质类固醇等全身性治疗相比，白细胞介素抑制剂通常具有更有利的副作用。由于它们选择性地作用于特定的白细胞介素，因此这些药物引起广泛的全身性副作用的风险较低。这些因素共同促进了该细分市场的成长。

给药途径

根据治疗途径，到 2022 年，局部治疗将成为全球银屑病药物市场的主导者。局部治疗直接应用于受影响的皮肤表面。这种非侵入性的给药途径不那么令人恐惧，更容易被许多患者接受，特别是那些可能不愿意使用注射或口服药物的患者。

局部治疗旨在局部作用于皮肤表面和皮下组织。它们直接针对皮肤中发生的发炎过程，这是牛皮癣的特征。这种有针对性的行动最大限度地减少了系统暴露，降低了系统副作用的风险。局部治疗有多种配方，包括乳膏、软膏、凝胶、泡沫和喷雾。这种多功能性使医疗保健提供者能够根据患者的个人喜好和不同银屑病表现的具体需求量身定制治疗选择。局部治疗对于轻度至中度牛皮癣病例特别有效，这些病例占患者群体的很大一部分。他们为这些患者提供了实用且易于接受的治疗选择，而无需更具侵入性的治疗。局部治疗通常用作维持治疗，以在更强化的治疗（例如生物製剂或光疗）获得缓解后控制银屑病症状。当与其他治疗结合使用时，它们还可以作为辅助治疗，以提高整体疗效。

区域洞察

2022年，北美成为全球银屑病药物市场的主导者，以价值计算，占据最大的市场份额。该地区拥有先进的医疗基础设施和完善的製药业。这使得广泛的研究和开发、新疗法的快速采用以及各种牛皮癣药物的可用性成为可能。北美很大一部分人口拥有健康保险，这有助于获得牛皮癣治疗，包括可能昂贵的生物製剂。北美国家处于银屑病临床研究的前沿，并进行了大量的临床试验和研究。这种研究驱动的环境有助于占据市场主导地位。

亚太市场有望成为成长最快的市场，在预测期内为牛皮癣药物参与者提供利润丰厚的成长机会。亚太地区人口众多，其中包括印度和中国等国家，牛皮癣盛行率不断上升。该地区庞大的患者数量正在推动市场成长。随着亚太国家医疗保健意识的提高，越来越多的患者因牛皮癣寻求医疗照护。这种趋势可能会继续增加对牛皮癣药物的需求。中国和印度等国家经济的快速成长导致中产阶级不断壮大，可支配收入也增加。这使得更多的人能够负担得起牛皮癣治疗，包括生物製剂。亚太地区是製药公司的新兴市场。许多全球製药公司正在扩大在该地区的业务，增加牛皮癣药物的取得并推动市场成长。亚太地区的一些国家正在发起医疗保健计划，以改善获得优质医疗服务的机会，包括治疗牛皮癣等慢性病。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和次要管理途径
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球银屑病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依治疗类型（生物药物、小分子全身性药物、热带疗法）
    • 依作用机转（TNF Alpha 抑制剂、PDE4 抑制剂、白血球介素抑制剂等）
    • 依给药途径（口服、肠外、局部）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美银屑病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 按作用机制
    • 依给药途径
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲银屑病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 按作用机制
    • 依给药途径
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区干癣药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 按作用机制
    • 依给药途径
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲干癣药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 按作用机制
    • 依给药途径
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲银屑病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 按作用机制
    • 依给药途径
  • MEA：国家分析
    • 南非牛皮癣药物
    • 沙乌地阿拉伯 牛皮癣药物
    • 阿联酋牛皮癣药物

第 11 章：市场动态

  • 驱动因素与挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球银屑病药物市场：SWOT 分析

第14章：竞争格局

  • 商业概览
  • 行动奉献机制
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Biogen Idec
    • Boehringer Ingelheim
    • Celgene Corporation
    • Dr.Reddy`s Laboratories
    • Eli Lilly and Company
    • Forward Pharma
    • Johnson and Johnson (Janssen Biotech Inc.)
    • Leo Pharma AS
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 16213

In 2022, the Global Psoriasis Drugs Market achieved a valuation of USD 21.06 billion, and it is poised for substantial growth in the upcoming period, with a projected Compound Annual Growth Rate (CAGR) of 6.57% through 2028. The Global Psoriasis Drugs Market represents a dynamic and rapidly evolving sector within the pharmaceutical industry, primarily fueled by the escalating prevalence of psoriasis, advancements in treatment options, and a growing demand for more effective therapeutic interventions. This market overview offers insights into the present state and the key factors shaping the Global Psoriasis Drugs Market.

Psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches on the skin, affects millions of individuals worldwide. The global incidence of psoriasis has been consistently on the rise, resulting in a significant patient population in need of effective treatment options. The condition not only presents physical symptoms but also has a substantial impact on the quality of life for affected individuals, underscoring the critical need for treatment. The landscape of psoriasis treatment has witnessed remarkable progress, encompassing a broad spectrum of therapeutic choices, including topical treatments (such as creams and ointments), phototherapy (light-based therapy), systemic treatments (oral medications), and biologic drugs. Biologics, which target specific components of the immune system, have gained prominence due to their superior efficacy and safety profiles.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 21.06 Billion
Market Size 2028USD 30.79 Billion
CAGR 2023-20286.57%
Fastest Growing SegmentOral
Largest MarketNorth America

Increasing Prevalence of Psoriasis

The increasing prevalence of psoriasis refers to the rising number of individuals worldwide who are diagnosed with this chronic autoimmune skin condition. Psoriasis is characterized by the rapid buildup of skin cells, leading to symptoms such as scaling, redness, and inflammation. Psoriasis has a genetic component, and individuals with a family history of the condition are more likely to develop it. As families expand and genetic information is passed down, the likelihood of psoriasis cases increases.

Environmental triggers, such as stress, smoking, and certain infections, can exacerbate psoriasis or trigger its onset. In our modern lifestyles, exposure to these triggers has become more common, contributing to the increasing prevalence. Changes in dietary habits, sedentary lifestyles, and increased exposure to pollution and urban environments may influence the development of psoriasis. These lifestyle factors can affect the immune system and skin health, potentially leading to psoriasis. Advances in medical knowledge and diagnostic techniques have led to better recognition and diagnosis of psoriasis cases. Healthcare providers are now more adept at identifying the condition, even in its milder forms, contributing to the apparent increase in prevalence.

Advancements in Research and Development

Research and development (R&D) efforts in the pharmaceutical industry have witnessed significant advancements, particularly in the field of dermatology and autoimmune diseases. These advancements include a deeper understanding of the molecular mechanisms underlying psoriasis, the discovery of novel drug targets, and the development of more targeted and effective therapies. Advancements in R&D are pivotal in driving market growth because they result in the creation of better psoriasis drugs. These innovations lead to drugs with improved efficacy, reduced side effects, and enhanced patient outcomes. The promise of innovative treatments encourages investment in the psoriasis drug market, attracting both pharmaceutical companies and investors.

Evolving Regulatory Environment

Regulatory bodies responsible for drug approvals have adapted to the changing healthcare landscape. They have recognized the urgent need for safe and effective psoriasis treatments. Consequently, the regulatory process for approving psoriasis drugs has become more efficient and accommodating. An evolving regulatory environment is crucial for market growth because it expedites the time it takes to bring new psoriasis drugs to market. Streamlined approvals mean that pharmaceutical companies can commercialize their products faster, allowing them to meet the demands of patients more promptly and stay competitive in the market.

Growing Patient Awareness

Patients today have greater access to information about psoriasis and its available treatments. This is primarily due to the internet, patient advocacy groups, and healthcare education initiatives. Patients are becoming more proactive in seeking treatment options and advocating for their healthcare needs. The increase in patient awareness is a significant driver of market growth because informed patients are more likely to seek medical help for their psoriasis. They actively engage with healthcare providers, leading to earlier diagnosis and treatment initiation. This trend not only benefits patients but also fuels the demand for psoriasis drugs.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

Psoriasis is a multifactorial autoimmune disease, and its exact cause remains elusive. The complexity of its pathophysiology makes it challenging to develop targeted therapies. Psoriasis flare-ups can be triggered or exacerbated by various factors, including stress, infections, and lifestyle choices. Understanding and addressing these triggers on an individual basis is a complex task.

Genetic predisposition plays a role in psoriasis, but the genetic factors involved are diverse. Tailoring treatments to specific genetic profiles are a challenge that limits the development of personalized therapies.

High Research and Development Costs

Developing new psoriasis drugs requires extensive clinical trials to ensure safety and efficacy. These trials are costly and time-consuming, often taking several years to complete.

Meeting the stringent regulatory requirements for pharmaceuticals, including psoriasis treatments, involves substantial financial investments. This can deter smaller pharmaceutical companies from entering the market. The competitive nature of the pharmaceutical industry means that companies need to invest significantly in research and development to stay ahead. This high level of competition can be a barrier for smaller firms.

Access to Treatment and Healthcare Disparities

Some of the newer biologic therapies for psoriasis can be prohibitively expensive, limiting access for individuals without comprehensive insurance coverage. Affordability issues can slow down the market's growth potential.

Access to psoriasis treatment may vary significantly by region. In underserved areas or countries with limited healthcare infrastructure, patients may struggle to access appropriate care, hindering market expansion. Lack of awareness and education about psoriasis among patients and healthcare providers can result in delayed or suboptimal treatment. Efforts to increase awareness and understanding are essential for market growth.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches:

One prominent trend in the Global Psoriasis Market is the increasing utilization of biologic therapies. Biologics are medications derived from living organisms and target specific immune system components involved in psoriasis. They have demonstrated remarkable efficacy in managing psoriasis symptoms with fewer side effects compared to traditional treatments like steroids. As a result, the market is witnessing a shift towards biologic therapies, offering patients more effective and targeted treatment options.

Personalized Medicine and Precision Therapies:

Personalized medicine is gaining traction in the treatment of psoriasis. Advances in genetics and biomarker research are enabling healthcare providers to tailor treatments to the specific genetic and molecular profiles of individual patients. This trend allows for more precise and effective therapies, minimizing trial-and-error approaches and improving patient outcomes.

Telemedicine and Digital Health Solutions:

The adoption of telemedicine and digital health solutions has accelerated in the psoriasis market, especially in the wake of the COVID-19 pandemic. Patients now have greater access to remote consultations with dermatologists and healthcare providers. Additionally, digital tools and mobile apps help patients track their psoriasis symptoms and treatment progress. This trend enhances patient engagement, monitoring, and overall management of psoriasis, improving the quality of care and patient experience.

These trends reflect the ongoing evolution of the Global Psoriasis Market towards more effective, patient-centered, and technologically advanced approaches to psoriasis management. They signify a positive shift towards better outcomes and improved quality of life for individuals living with psoriasis.

Segmental Insights

Type of Treatment Insights

Based on the type of treatment, the biologic drugs segment emerged as the dominant player in the global market for Psoriasis Drugs in 2022. The dominance of biologic drugs in the Global Psoriasis Drugs Market can be attributed to several key factors related to their type of treatment. Biologic drugs are designed to target specific components of the immune system that play a role in the development of psoriasis. This targeted approach results in higher treatment efficacy and a more favourable side effect profile compared to non-biologic treatments like corticosteroids or topical creams.

Biologic drugs often provide longer-lasting effects with less frequent dosing. Some biologics require injections or infusions every few weeks or months, reducing the burden of treatment for patients compared to daily or more frequent applications of other medications. Biologics typically have a lower risk of causing systemic side effects because they act specifically on the immune system components involved in psoriasis. This is in contrast to systemic treatments like oral corticosteroids, which can have broader and potentially more severe side effects.

Biologic drugs have shown significant efficacy in reducing the physical and psychological burdens of psoriasis. Patients often experience a substantial improvement in their quality of life, including reduced itching, pain, and inflammation, as well as improved skin appearance. This positive impact on patients' well-being drives the demand for biologics. As patients become more informed about treatment options and their outcomes, many express a preference for biologics due to their effectiveness and safety profile. This patient preference has contributed to the dominance of biologic drugs in the market. Healthcare providers have gained confidence in prescribing biologics for psoriasis treatment due to the extensive clinical research supporting their efficacy and safety. This confidence among physicians further promotes the use of biologics. Pharmaceutical companies have heavily invested in research and development to create and improve biologic therapies for psoriasis. This ongoing innovation has resulted in the development of new biologics with enhanced properties, further solidifying their dominance in the market. These factors are expected to drive the growth of this segment.

Mechanism of Action Insights

Based on the mechanism of action, the interleukin inhibitors segment emerged as the dominant player in the global market for Psoriasis Drugs in 2022. Interleukin inhibitors specifically target the immune pathways involved in the development of psoriasis. Psoriasis is characterized by an overactive immune response, with interleukins playing a crucial role. By inhibiting these specific interleukins, such as IL-17 and IL-23, these drugs effectively disrupt the disease process at its core. Interleukin inhibitors have demonstrated remarkable efficacy in clinical trials, often leading to rapid improvement in psoriasis symptoms. Patients frequently experience a significant reduction in inflammation, itching, and skin lesions shortly after starting treatment.

Many interleukin inhibitors have a prolonged duration of action, allowing for less frequent dosing. Some drugs in this category require injections or infusions every few weeks or months, offering convenience and improved adherence for patients. Interleukin inhibitors have shown the ability to maintain remission in many patients, reducing the risk of psoriasis flare-ups. This feature is particularly valuable for individuals seeking long-term disease control. Interleukin inhibitors generally have a more favorable side effect profile compared to systemic treatments like oral corticosteroids. Because they act selectively on specific interleukins, these drugs have a reduced risk of causing broad systemic side effects. These factors collectively contribute to the growth of this segment.

Route Of Administration

Based on the Route of Administration of treatment, the topical segment emerged as the dominant player in the global market for Psoriasis Drugs in 2022. Topical treatments are applied directly to the affected skin surface. This non-invasive route of administration is less intimidating and more acceptable to many patients, especially those who may be reluctant to use injections or oral medications.

Topical treatments are designed to act locally on the skin's surface and the underlying tissue. They directly target the inflammatory processes occurring in the skin, which are characteristic of psoriasis. This targeted action minimizes systemic exposure, reducing the risk of systemic side effects. Topical treatments come in various formulations, including creams, ointments, gels, foams, and sprays. This versatility allows healthcare providers to tailor treatment choices to individual patient preferences and the specific needs of different psoriasis manifestations. Topical treatments are particularly effective for mild to moderate psoriasis cases, which represent a significant portion of the patient population. They offer a practical and accessible treatment option for these patients without the need for more invasive therapies. Topical treatments are often used as maintenance therapy to keep psoriasis symptoms under control after more intensive treatments, such as biologics or phototherapy, have achieved remission. They can also serve as adjunct therapy when combined with other treatments to enhance overall effectiveness.

Regional Insights

North America emerged as the dominant player in the global Psoriasis Drugs market in 2022, holding the largest market share in terms of value. The region boasts advanced healthcare infrastructure and a well-established pharmaceutical industry. This allows for extensive research and development, rapid adoption of new treatments, and availability of a wide range of psoriasis drugs. A significant proportion of the population in North America has health insurance coverage, which facilitates access to psoriasis treatments, including biologics, which can be expensive. North American countries are at the forefront of clinical research in psoriasis, conducting numerous clinical trials and studies. This research-driven environment contributes to the dominance of the market.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Psoriasis Drugs players during the forecast period. Factors such The Asia-Pacific region has a massive population, including countries like India and China, where there is a rising prevalence of psoriasis. The sheer number of patients in this region is driving market growth. As healthcare awareness increases in Asia-Pacific countries, more patients are seeking medical attention for psoriasis. This trend is likely to continue to boost the demand for psoriasis drugs. Rapid economic growth in countries like China and India has led to an expanding middle class with greater disposable income. This enables more individuals to afford psoriasis treatments, including biologics. Asia-Pacific represents an emerging market for pharmaceutical companies. Many global pharmaceutical firms are expanding their presence in this region, increasing access to psoriasis drugs and driving market growth. Some countries in the Asia-Pacific region are launching healthcare initiatives to improve access to quality medical care, including treatments for chronic conditions like psoriasis.

Key Market Players

  • Glanbia Plc
  • Pfizer Inc.
  • Bayer AG
  • Amway Corp.
  • GlaxoSmithKline plc.
  • Good Health New Zealand
  • The Nature's Bounty Co.
  • NOW Foods
  • Abbott
  • Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

  • TNF Alpha Inhibitors
  • PDE4 Inhibitors
  • Interleukin Inhibitors
  • Others

Psoriasis Drugs Market, By Route of Administration:

  • Oral
  • Parenteral
  • Topical

Psoriasis Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

  • Global Psoriasis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Route of Administrations
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
    • 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Treatment
    • 6.2.2. By Mechanism of Action
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psoriasis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Treatment
        • 6.3.1.2.2. By Mechanism of Action
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Canada Psoriasis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Treatment
        • 6.3.2.2.2. By Mechanism of Action
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Mexico Psoriasis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Treatment
        • 6.3.3.2.2. By Mechanism of Action
        • 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Treatment
    • 7.2.2. By Mechanism of Action
    • 7.2.3. By Route of Administration
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psoriasis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Treatment
        • 7.3.1.2.2. By Mechanism of Action
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Treatment
        • 7.3.2.2.2. By Mechanism of Action
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. Italy Psoriasis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type of Treatment
        • 7.3.3.2.2. By Mechanism of Action
        • 7.3.3.2.3. By Route of Administration
    • 7.3.4. France Psoriasis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Treatment
        • 7.3.4.2.2. By Mechanism of Action
        • 7.3.4.2.3. By Route of Administration
    • 7.3.5. Spain Psoriasis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Treatment
        • 7.3.5.2.2. By Mechanism of Action
        • 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Treatment
    • 8.2.2. By Mechanism of Action
    • 8.2.3. By Route of Administration
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Psoriasis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Treatment
        • 8.3.1.2.2. By Mechanism of Action
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. India Psoriasis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Treatment
        • 8.3.2.2.2. By Mechanism of Action
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Japan Psoriasis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Treatment
        • 8.3.3.2.2. By Mechanism of Action
        • 8.3.3.2.3. By Route of Administration
    • 8.3.4. South Korea Psoriasis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Treatment
        • 8.3.4.2.2. By Mechanism of Action
        • 8.3.4.2.3. By Route of Administration
    • 8.3.5. Australia Psoriasis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Treatment
        • 8.3.5.2.2. By Mechanism of Action
        • 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Treatment
    • 9.2.2. By Mechanism of Action
    • 9.2.3. By Route of Administration
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psoriasis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Treatment
        • 9.3.1.2.2. By Mechanism of Action
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. Argentina Psoriasis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Treatment
        • 9.3.2.2.2. By Mechanism of Action
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. Colombia Psoriasis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Treatment
        • 9.3.3.2.2. By Mechanism of Action
        • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Treatment
    • 10.2.2. By Mechanism of Action
    • 10.2.3. By Route of Administration
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psoriasis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Treatment
        • 10.3.1.2.2. By Mechanism of Action
        • 10.3.1.2.3. By Route of Administration
    • 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Treatment
        • 10.3.2.2.2. By Mechanism of Action
        • 10.3.2.2.3. By Route of Administration
    • 10.3.3. UAE Psoriasis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Treatment
        • 10.3.3.2.2. By Mechanism of Action
        • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers & Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Mechanism of Action Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Biogen Idec
    • 14.5.2. Boehringer Ingelheim
    • 14.5.3. Celgene Corporation
    • 14.5.4. Dr.Reddy`s Laboratories
    • 14.5.5. Eli Lilly and Company
    • 14.5.6. Forward Pharma
    • 14.5.7. Johnson and Johnson (Janssen Biotech Inc.)
    • 14.5.8. Leo Pharma AS
    • 14.5.9. Merck and Co. Inc.
    • 14.5.10. Novartis AG
    • 14.5.11. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer